Neutral results for prasugrel vs clopidogrel in medically managed ACS patients mean the newer antiplatelet agent cannot be recommended for use in this patient population, say the TRILOGY ACS researchers. However, they did pinpoint a seemingly time-dependent clinical benefit with prasugrel beginning a year after therapy started, which they say deserves further analysis.
via The Heart
via The Heart
No comments:
Post a Comment